Dimensional Fund Advisors LP Purchases 10,990 Shares of Haemonetics Co. (NYSE:HAE)

Dimensional Fund Advisors LP grew its position in shares of Haemonetics Co. (NYSE:HAE) by 1.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 992,229 shares of the medical instruments supplier’s stock after acquiring an additional 10,990 shares during the quarter. Dimensional Fund Advisors LP owned about 1.98% of Haemonetics worth $77,470,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of HAE. Covestor Ltd raised its holdings in Haemonetics by 146.8% during the fourth quarter. Covestor Ltd now owns 738 shares of the medical instruments supplier’s stock worth $58,000 after buying an additional 439 shares during the last quarter. Whittier Trust Co. bought a new position in Haemonetics in the 4th quarter valued at about $62,000. Parkside Financial Bank & Trust boosted its stake in Haemonetics by 25.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,176 shares of the medical instruments supplier’s stock valued at $92,000 after purchasing an additional 240 shares during the last quarter. AlphaQuest LLC boosted its stake in Haemonetics by 36,520.0% during the 4th quarter. AlphaQuest LLC now owns 1,831 shares of the medical instruments supplier’s stock valued at $143,000 after purchasing an additional 1,826 shares during the last quarter. Finally, KBC Group NV increased its holdings in Haemonetics by 54.6% during the 4th quarter. KBC Group NV now owns 2,016 shares of the medical instruments supplier’s stock worth $157,000 after purchasing an additional 712 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Haemonetics Trading Up 2.2 %

Shares of Haemonetics stock opened at $64.00 on Wednesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.55 and a current ratio of 3.97. The stock has a market capitalization of $3.22 billion, a P/E ratio of 25.20, a P/E/G ratio of 1.11 and a beta of 0.41. Haemonetics Co. has a 52-week low of $55.30 and a 52-week high of $97.97. The stock’s 50-day simple moving average is $62.82 and its 200 day simple moving average is $71.97.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. As a group, research analysts anticipate that Haemonetics Co. will post 4.55 EPS for the current year.

Wall Street Analysts Forecast Growth

HAE has been the subject of a number of analyst reports. Barrington Research lowered their price target on Haemonetics from $108.00 to $95.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JMP Securities lowered their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating for the company in a report on Friday, February 7th. Raymond James reaffirmed a “strong-buy” rating and issued a $115.00 price objective (down from $120.00) on shares of Haemonetics in a research report on Friday, February 7th. Needham & Company LLC dropped their target price on shares of Haemonetics from $108.00 to $104.00 and set a “buy” rating on the stock in a research report on Tuesday, March 18th. Finally, StockNews.com lowered Haemonetics from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Haemonetics currently has a consensus rating of “Moderate Buy” and an average target price of $101.22.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.